Corcept Therapeutics CORT remains focused on building long-term growth visibility beyond its lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome. The drug recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year.
Corcept has also been expanding its efforts to identify and treat patients with Cushing’s syndrome, providing a potential runway for continued Korlym demand.
Korlym is likely to remain an important contributor to Corcept’s top-line growth, supported by increasing demand for the treatment of Cushing’s syndrome and continued growth in prescriptions. However, Corcept’s heavy reliance on Korlym for revenue growth remains a concern. A decline in the drug’s sales will significantly hinder the company’s prospects.
CORT Eyes Lifyorli to Potentially Lower Dependence on Korlym
In March 2026, the FDA approved Lifyorli (relacorilant), Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. The approval of Lifyorli should help Corcept diversify its revenue base.
Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial availability. Though still in the early stages, we expect Lifyorli to help reduce CORT’s heavy dependence on Korlym over time.
Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Lifyorli in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.
A final decision from the European Commission is expected in the fourth quarter of 2026.
CORT’s Other Development Activities With Relacorilant
Relacorilant, in combination with other anticancer therapies, is also being studied in other solid tumors, including platinum-sensitive ovarian, prostate, endometrial, cervical and pancreatic cancers.
The phase II BELLA study (part A) is evaluating relacorilant plus nab-paclitaxel and Roche’s RHHBY Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer.
The BELLA study is designed to understand whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY’s Avastin — offers patients an additional treatment option or not.
The company is also evaluating relacorilant plus Pfizer’s PFE Xtandi (enzalutamide) in patients with early-stage prostate cancer. A phase II study is being conducted in collaboration with the University of Chicago.
Xtandi, which is approved for different stages of prostate cancer, has been one of Pfizer’s key revenue drivers.
Importantly, Corcept is also developing relacorilant, a selective glucocorticoid receptor antagonist for treating Cushing's syndrome. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026.
Successful clinical development and approval of relacorilant for additional indications could help Corcept establish additional revenue streams and reduce its dependence on Korlym.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).